MX2009008774A - La proteina secretada ccdc80 regula la diferenciacion de adipocito. - Google Patents

La proteina secretada ccdc80 regula la diferenciacion de adipocito.

Info

Publication number
MX2009008774A
MX2009008774A MX2009008774A MX2009008774A MX2009008774A MX 2009008774 A MX2009008774 A MX 2009008774A MX 2009008774 A MX2009008774 A MX 2009008774A MX 2009008774 A MX2009008774 A MX 2009008774A MX 2009008774 A MX2009008774 A MX 2009008774A
Authority
MX
Mexico
Prior art keywords
ccdc80
secreted protein
adipocyte differentiation
methods
disclosed
Prior art date
Application number
MX2009008774A
Other languages
English (en)
Inventor
Frederic Tremblay
Ruth E Gimeno
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009008774A publication Critical patent/MX2009008774A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen aquí métodos para modular adipogenia. Los métodos incluyen poner en contacto una célula que expresa el gen Ccdc80 con un agente que modula la expresión o actividad del gen Ccdc80 o proteína Ccdc80. Se describen adicionalmente aquí métodos para tratar afecciones tal como obesidad, resistencia a la insulina, y/o diabetes tipo 2 con moduladores Ccdc80. También se describen aquí métodos para identificar los moduladores Ccdc80.
MX2009008774A 2007-02-16 2008-02-15 La proteina secretada ccdc80 regula la diferenciacion de adipocito. MX2009008774A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90188207P 2007-02-16 2007-02-16
US99792007P 2007-10-05 2007-10-05
PCT/US2008/002124 WO2008100627A2 (en) 2007-02-16 2008-02-15 The secreted protein ccdc80 regulates adipocyte differentiation

Publications (1)

Publication Number Publication Date
MX2009008774A true MX2009008774A (es) 2009-08-25

Family

ID=39539642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008774A MX2009008774A (es) 2007-02-16 2008-02-15 La proteina secretada ccdc80 regula la diferenciacion de adipocito.

Country Status (6)

Country Link
US (1) US20080221057A1 (es)
EP (1) EP2120995A2 (es)
JP (1) JP2010518821A (es)
CA (1) CA2677818A1 (es)
MX (1) MX2009008774A (es)
WO (1) WO2008100627A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241129A1 (en) * 2007-02-16 2008-10-02 Wyeth Adipocyte secreted protein ccdc80 is a potent stimulator of bone formation
CN115896106A (zh) 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体
WO2020018005A1 (en) * 2018-07-17 2020-01-23 Limited Liability Company "Gero" Devices, methods, compositions and systems for the treatment of aging and age- related disorders
CN112592397B (zh) * 2020-12-31 2022-08-30 上海市胸科医院 Ccdc80来源的多肽及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5268295A (en) * 1991-05-31 1993-12-07 W. Alton Jones Cell Science Center, Inc. Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO2002098409A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination therapy for type ii diabetes or syndrome x
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
WO2002098414A1 (en) * 2001-06-07 2002-12-12 Wyeth Methods using ptpase inhibitors and insulin
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
WO2002098510A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and an aldose reductase inhibitor
AR034375A1 (es) * 2001-06-07 2004-02-18 Wyeth Corp Combinacion de un inhibidor de ptpasa y un agente de sulfonilurea
JP2005000052A (ja) * 2003-06-11 2005-01-06 Japan Science & Technology Agency Ａｄｒｐ遺伝子の発現を抑制するオリゴヌクレオチド及び方法
US20050250123A1 (en) * 2003-11-21 2005-11-10 Regents Of The University Of California Reducing galectin-12 activity to reduce formation of adipocytes
WO2007041282A2 (en) * 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis

Also Published As

Publication number Publication date
EP2120995A2 (en) 2009-11-25
JP2010518821A (ja) 2010-06-03
WO2008100627A2 (en) 2008-08-21
WO2008100627A3 (en) 2008-10-09
CA2677818A1 (en) 2008-08-21
US20080221057A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
WO2008115518A3 (en) Biomarkers of sirtuin activity and methods of use thereof
IL235342B (en) Using hsp70 as a regulator of enzymatic activity
WO2008063330A3 (en) Molecular control of brown fat differentiation and energy expenditure
GB0809069D0 (en) Gene signatures
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009153748A3 (en) Methods and devices for use with sealants
MX2009008774A (es) La proteina secretada ccdc80 regula la diferenciacion de adipocito.
WO2009097014A3 (en) Therapeutic kinase modulators
WO2008047235A3 (en) Methods of treating disorders associated with fat storage
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2008027379A3 (en) Indicators of sirtuin activity and methods of use thereof
EP1898950A4 (en) GALK1S MODIFIERS OF THE PTEN / AKT PATHWAY AND METHODS OF USE
WO2008154516A3 (en) Btnl2 fusion protein for t-cell activity modulation
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2007140308A3 (en) Methods of screening for trpm4 modulators of insulin secretion
IL192414A0 (en) Siva ubiquitination and/or degradation-related activity and modulators thereof
WO2002055664A3 (en) Modulating insulin receptor signaling
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2008016996A3 (en) Methods of modulating metabolic memory
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2008091598A3 (en) CONFORMATION AND ACTIVITY OF Gβ5 COMPLEXES
WO2008036422A3 (en) Vipr1s as modifiers of the e2f/rb pathway and methods of use
WO2006099182A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal